Molecular subtypes in breast cancer evaluation and management: Divide and conquer

Cancer Investigation

Volumn 26, Issue 1, 2008, Pages 1-10

  Peppercorn, Jeffrey ^a   Perou, Charles M ^a   Carey, Lisa A ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CYCLOPHOSPHAMIDE; CYTOKERATIN 18; CYTOKERATIN 5; CYTOKERATIN 6; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; MUCIN 1; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN P53; TRASTUZUMAB; UVOMORULIN;

BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER RESISTANCE; CANCER RISK; DNA HYBRIDIZATION; ENVIRONMENTAL FACTOR; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC RISK; GENOME ANALYSIS; GOLD STANDARD; HUMAN; LYMPH NODE METASTASIS; MICROARRAY ANALYSIS; MITOSIS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; REVIEW; TUMOR BIOPSY;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 37849041082     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701784238     Document Type: Review

References (57)

1. Beatson, G. On the treatment of inoperable cases of carcinoma of the mammary: sugges tions for a new method of treatment, with illustrative cases. Lancet 1896, 104-107.
2. Ravdin, P.M.; Siminoff, L.A.; Davis, G.J; et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001, 19, 980-991.
3. Bergh, J.; Holmquist, M. Who should not receive adjuvant chemotherapy? International databases. J Natl Cancer Inst Monogr 2001, 30, 103-108.
4. Perou, C.M.; Sorlie, T.; Eisen, M.B.; et al. Molecular portraits of human breast tumours. Nature 2000, 406, 747-752.
5. Golub, T.R.; Slonim, D.K.; Tamayo, P.; et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286, 531-537.
6. Simon, R.; Radmacher, M.D.; Dobbin, K. Design of studies using DNA microarrays. Genet Epidemiol 2002, 23, 21-36.
7. Sorlie, T.; Perou, C.M.; Tibshirani, R.; et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98, 10869-10874.
8. Sorlie, T.; Tibshirani, R.; Parker, J.; et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100, 8418-8423.
9. Yu, K.; Lee, CH.; Tan, P.H.; et al. Conservation of breast cancer molecular subtypes and tran- scriptional patterns of tumor progression across distinct ethnic populations. Clin Cancer Res 2004, 10, 5508-5517.
10. Van, Laere; S.J.; Van den Eynden, G.G.; Van der Auwera, I.; et al. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res Treat 2006, 95(3), 243-255.
11. Weigelt, B.; Hu, Z.; He, X.; et al. Molecular portraits and 70-gene prognosis signature are pre served throughout the metastatic process of breast cancer. Cancer Res 2005, 65, 9155-9158.
12. Abd El-Rehim, D.M.; Ball, G.; Finder, S.E; et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologi cally distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005, 116, 340-350.
13. Hu, Z.; Fan, C.; Oh, D.S.; et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genom 2006, 7, 96.
14. Nielsen, T.O.; Hsu, F.D.; Jensen, K.; et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10, 5367-5374.
15. King, M.C.; Marks, J.H.; Mandell, J.B.; Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003, 302, 643-646.
16. Chappuis, P.O.; Nethercot V.; Foulkes W.D. Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol 2000, 18, 287-295.
17. Foulkes, W.D.; Stefansson, I.M.; Chappuis, P.O.; et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003, 95, 1482-1485.
18. Olopade, O.I.; Grushko, T.; Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001, 344, 2028-2029.
19. van 't Veer, L.J.; Dai, H.; van de Vijver, M.J.; et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415, 530-536.
20. Carey, L.A.; Perou, C.M.; Livasy, C.A.; et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. J Am Med Assoc 2006, 295, 2492-2502.
21. Chlebowski, R.T.; Chen, Z.; Anderson, G.L.; et al. Ethnicity and breast cancer: factors influen cing differences in incidence and outcome. J Natl Cancer Inst 2005, 97, 439-448.
22. Gapstur, S.M.; Dupuis, J.; Gann, P.; et al. Hormone receptor status of breast tumors in black, Hispanic, and non-Hispanic white women. An analysis of 13,239 cases. Cancer 1996, 77, 1465-1471.
23. Colditz, G.A.; Rosner, B.A.; Chen, W.Y.; et al. Risk factors for breast cancer according to estro gen and progesterone receptor status. J Natl Cancer Inst 2004, 96, 218-228.
24. Chen, W.Y.; Hankinson, S.E.; Schnitt, S.J.; et al. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 2004, 101, 1490-1500.
25. Fisher, B.; Costantino, J.P.; Wickerham, D.L.; et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-l Study. J Natl Cancer Inst 1998, 90, 1371-1388.
26. Suzuki, R.; Ye, W.; Rylander-Rudqvist, T.; et al. Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study. J Natl Cancer Inst 2005, 97, 1601-1608.
27. Fung, T.T.; Hu, F.B.; McCullough, M.L.; et al. Diet quality is associated with the risk of estrogen receptor-negative breast cancer in postmenopausal women. J Nutr 2006, 136, 466-472.
28. Marshall, S.F.; Bernstein, L.; Anton-Culver, H.; et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 2005, 97, 805-812.
29. Zhang, S.M.; Hankinson, S.E.; Hunter, D.J.; et al. Folate intake and risk of breast cancer characterized by hormone receptor status. Cancer Epidemiol Biomarkers Prev 2005, 14, 2004-2008.
30. Faneyte, I.F.; Peterse, J.L.; Van Tinteren, H.; et al. Predicting early failure after adjuvant chemo therapy in high-risk breast cancer patients with extensive lymph node involvement. Clin Cancer Res 2004, 10, 4457-4463.
31. Sotiriou, C.; Neo, S.Y.; McShane, L.M.; et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003, 100, 10393-10398.
32. Rodriguez-Pinilla, S.M.; Sarrio, D.; Honrado, E.; et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 2006, 12, 1533-1539.
33. Minn, A.J.; Gupta, G.P.; Siegel, P.M.; et al. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436, 518-524.
34. van de Vijver, M.J.; He, Y.D.; van't Veer, L.J.; et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347, 1999-2009.
35. Foekens, J.A.; Atkins, D.; Zhang, Y.; et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 2006, 24, 1665-1671.
36. Paik, S.; Shak, S.; Tang, G.; et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351, 2817-2826.
37. Chang, H.Y.; Nuyten, D.S.; Sneddon, J.B.; et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005, 102, 3738-3743.
38. Ma, X.J.; Wang, Z.; Ryan, P.D.; et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004, 5, 607-616.
39. Fan, C.; Oh, D.S.; Wessels, L.; et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006, 355 (6), 560- 569.
40. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormo nal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365, 1687-1717.
41. Colleoni, M.; Minchella, I.; Mazzarol, G.; et al. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol 2000, 11, 1057-1059.
42. Guarneri, V.; Broglio, K.; Kau, S.W.; et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006, 24, 1037-1044.
43. Berry, D.A.; Cirrincione, C.; Henderson, I.C.; et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. J Am Med Assoc 2006, 295, 1658-1667.
44. Rouzier, R.; Perou, C.M.; Symmans, W.F.; et al. Breast cancer molecular subtypes respond dif ferently to preoperative chemotherapy. Clin Cancer Res 2005, 11, 5678-5685.
45. Carey, L.A.; Dees, E.C.; Sawyer, L.R.; et al. The triple negative paradox: primary tumor chemosensitivity of the basal-like breast cancer (BBC) phenotype. San Antonio Breast Cancer Symposium, 2004, pp. 1023a.
46. Troester, M.A.; Hoadley, K.A.; Sorlie, T.; et al. Cell-type-specific responses to chemotherapeu-tics in breast cancer. Cancer Res 2004, 64, 4218-4226.
47. Burris, H.A., III; Hurwitz, H.I.; Dees, E.C.; et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carci nomas. J Clin Oncol 2005, 23, 5305-5313.
48. Konecny, G.E.; Pegram, M.D.; Venkatesan, N.; et al: Activity of the dual kinase inhibitor lapa tinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006, 66, 1630-1639.
49. Kennedy, R.D.; Quinn, J.E.; Mullan, P.B.; et al. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004, 96, 1659-1668.
50. Charafe-Jauffret, E.; Ginestier, C.; Monville, F.; et al. Gene expression profiling of breast cell lines identifies potential newbasal markers. Oncogene 2006, 25, 2273-2284.
51. Livasy, C.A.; Karaca, G.; Nanda, R.; et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006, 19, 264-271.
52. Lev, D.C.; Kim, L.S.; Melnikova, V.; et al. Dual blockade of EGFR and ERK1/2 phosphory-lation potentiates growth inhibition of breast cancer cells. Br J Cancer 2004, 91, 795-802.
53. Simon, R.; Panussis, S.; Maurer, R.; et al. KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. Clin Cancer Res 2004, 10, 178-183.
54. Modi, S.; Seidman, A.D.; Dickler, M.; et al. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat 2005, 90, 157-163.
55. Reis-Filho, J.S.; Westbury, C.; Pierga, J.Y. The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol 2006, 59, 225-231.
56. Reid, J.F.; Lusa, L.; De, Cecco, L.; et al. Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst 2005, 97, 927-930.
57. Simon, R.; Radmacher, M.D.; Dobbin, K.; et al. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 2003, 95, 14-18.